LLY241101C745000
- 99.00
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly and Co Options Spot-On: On November 1st, 83,305 Contracts Were Traded, With 358.74K Open Interest
On November 1st ET, $Eli Lilly and Co(LLY.US)$ had active options trading, with a total trading volume of 83,305 options for the day, of which put options accounted for 50.3% of the total
Express News | The US Department of Justice: Eli Lilly and Co will pay civil fines to resolve allegations of misleading drivers about potential income.
Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,015
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Countdown to the USA election, when will the results be announced? Please keep this viewing guide handy!
"The big show" is about to begin, grab your "program."
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $994
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $970 to $1,146
Novo Nordisk Succeeds in Late-stage Trial for Weight Loss Therapy in MASH
Earnings Miss: Eli Lilly and Company Missed EPS By 31% And Analysts Are Revising Their Forecasts
Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com
AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com
Eli Lilly and Co Options Spot-On: On October 31st, 103.23K Contracts Were Traded, With 345.79K Open Interest
On October 31st ET, $Eli Lilly and Co(LLY.US)$ had active options trading, with a total trading volume of 103.23K options for the day, of which put options accounted for 42.0% of the total
Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
Eli Lilly 'Well-Positioned' for Growth Into 2025 Despite Q3 Volatility, UBS Says
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next. -- Barrons.com
Live On CNBC, Stephanie Link Announces Bought More Eli Lilly And Company
Biogen Slips as Morgan Stanley Downgrades on Leqembi Launch
Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds
Eli Lilly and Co's non-covalent BTK inhibitor approved in China, hot competition among domestic and foreign pharmaceutical companies for market layout.
The approval of Calquence brings a new option for Chinese MCL patients who have previously received covalent BTK therapy.